{"id":910,"date":"2021-03-01T17:34:08","date_gmt":"2021-03-01T15:34:08","guid":{"rendered":"https:\/\/wits-vida.org\/wordpress21\/?post_type=avada_faq&p=910"},"modified":"2023-10-10T16:13:18","modified_gmt":"2023-10-10T14:13:18","slug":"anthonet-koen","status":"publish","type":"avada_faq","link":"https:\/\/wits-vida.org\/team-member\/anthonet-koen\/","title":{"rendered":"Anthonet Koen"},"content":{"rendered":"

<\/span><\/div>

Anthonet Koen<\/h2><\/div>

Clinical Trials Lead<\/h4><\/div><\/div><\/div>

About<\/h4><\/div>

Anthonet Koen joined the Vaccines and Infectious Diseases Analytics (VIDA) Research Unit of the University of the Witwatersrand, as a medical officer in 2008 after completing her community service and undergraduate studies at the University of the Free State and having a special interest in the fields of paediatrics, clinical research and disease prevention.<\/p>\n

As part of the clinical team, which she currently leads, Anthonet had been sub-investigator on more than 20 clinical trials ranging from phase I-III, and principal investigator on three. These include trials on pneumococcal, meningococcal, rotavirus, influenza, RSV, group B streptococcus and measles vaccines. She is also the co-author on 14 vaccine-related publications.<\/p>\n<\/div>

<\/div><\/div>
ORCiD<\/span><\/a><\/div>
LinkedIn<\/span><\/a><\/div><\/div><\/div><\/div><\/div>

Publications<\/h4><\/div>
\n\t\t\t\t\n\t\t\t\t2023<\/a><\/label>\n\n\t\t\t\n\t\t\t\t\n\t\t\t\t2022<\/a><\/label>\n\n\t\t\t\n\t\t\t\t\n\t\t\t\t2021<\/a><\/label>\n\n\t\t\t\n\t\t\t\t\n\t\t\t\t2020<\/a><\/label>\n\n\t\t\t\n\t\t\t\t\n\t\t\t\t2019<\/a><\/label>\n\n\t\t\t\n\t\t\t\t\n\t\t\t\t2017<\/a><\/label>\n\n\t\t\t\n\t\t\t\t\n\t\t\t\t2016<\/a><\/label>\n\n\t\t\t\n\t\t\t\t\n\t\t\t\t2015<\/a><\/label>\n\n\t\t\t\n\t\t\t\t\n\t\t\t\t2014<\/a><\/label>\n\n\t\t\t\n\t\t\t\t\n\t\t\t\t2013<\/a><\/label>\n\n\t\t\t\n\t\t\t\t\n\t\t\t\t2011<\/a><\/label>\n\n\t\t\t<\/form>

Kaplonek P; Cizmeci D; Kwatra G; Izu A; Lee JS; Bertera HL; Fischinger S; Mann C; Amanat F; Wang W; Koen AL; Fairlie L; Cutland CL; Ahmed K; Dheda K; Barnabas SL; Bhorat QE; Briner C; Krammer F; Saphire EO; Gilbert SC; Lambe T; Pollard AJ; Nunes M; Wuhrer M; Lauffenburger DA; Madhi SA; Alter G<\/span>, 2023<\/span>. ChAdOx1 nCoV-19 (AZD1222) vaccine-induced Fc receptor binding tracks with differential susceptibility to COVID-19.<\/a><\/span>  Nat Immunol<\/span> 24(7):1161-1172<\/span><\/p>

<\/p>

Bhiman JN; Richardson SI; Lambson BE; Kgagudi P; Mzindle N; Kaldine H; Crowther C; Gray G; Bekker LG; Shinde V; Bennett C; Glenn GM; Madhi SA; Moore PL<\/span>, 2023<\/span>. Novavax NVX-COV2373 triggers neutralization of Omicron sub-lineages.<\/a><\/span>  Sci Rep<\/span> 13(1):1222<\/span><\/p>

<\/p>

Madhi SA; Kwatra G; Richardson SI; Koen AL; Baillie V; Cutland CL; Fairlie L; Padayachee SD; Dheda K; Barnabas SL; Bhorat QE; Briner C; Ahmed K; Aley PK; Bhikha S; Bhorat AE; Esmail A; Horne E; Kaldine H; Mukendi CK; Madzorera VS; Manamela NP; Masilela M; Hermanus ST; Motlou T; Mzindle N; Oelofse S; Patel F; Rhead S; Rossouw L; Taoushanis C; van Eck S; Lambe T; Gilbert SC; Pollard AJ; Moore PL; Izu A<\/span>, 2023<\/span>. Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b-2a trial.<\/a><\/span>  Lancet Infect Dis<\/span> 23(3):295-306<\/span><\/p>

<\/p>

McMahon WC; Kwatra G; Izu A; Koen AL; Greffrath J; Fairlie L; Patel F; Mukendi CK; Mbele NJ; Lala R; Burgers WA; Nunes MC; Cutland CL; Gilbert SC; Lambe T; Pollard AJ; Madhi SA<\/span>, 2023<\/span>. T-cell responses induced by ChAdOx1 nCoV-19 (AZD1222) vaccine to wild-type severe acute respiratory syndrome coronavirus 2 among people with and without HIV in South Africa.<\/a><\/span>  AIDS<\/span> 37(1):105-112<\/span><\/p>

<\/p>

Koen AL; Izu A; Baillie V; Kwatra G; Cutland CL; Fairlie L; Padayachee SD; Dheda K; Barnabas SL; Bhorat QE; Briner C; Ahmed K; Bhikha S; Bhiman JN; du Plessis J; Esmail A; Horne E; Hwa SH; Oommen-Jose A; Lambe T; Laubscher M; Malahleha M; Benade G; McKenzie S; Oelofse S; Patel F; Pillay S; Rhead S; Rodel H; Taoushanis C; Tegally H; Thombrayil A; Villafana TL; Gilbert S; Pollard AJ; Madhi SA<\/span>, 2023<\/span>. Efficacy of primary series AZD1222 (ChAdOx1 nCoV-19) vaccination against SARS-CoV-2 variants of concern: Final analysis of a randomized, placebo-controlled, phase 1b\/2 study in South African adults (COV005).<\/a><\/span>  Vaccine<\/span> 41(23):3486-3492<\/span><\/p>

<\/p>

Smith M; Kwatra G; Izu A; Nel A; Cutland C; Ahmed K; Baillie V; Barnabas S; Bhorat Q; Briner C; Lazarus E; Dheda K; Fairlie L; Koen A; Madhi S; Blackburn JM<\/span>, 2023<\/span>. Longitudinal IgA and IgG Response, and ACE2 Binding Blockade, to Full-Length SARS-CoV-2 Spike Protein Variants in a Population of Black PLWH Vaccinated with ChAdOx1 nCoV-19.<\/a><\/span>  Viruses<\/span> 15<\/span>.<\/p>

<\/p>

Olwagen CP; Izu A; Mutsaerts EAML; Jose L; Koen A; Downs SL; Van Der Merwe L; Laubscher M; Nana AJ; Moultrie A; Cutland CL; Dorfman JR; Madhi SA<\/span>, 2023<\/span>. Single priming and booster dose of ten-valent and 13-valent pneumococcal conjugate vaccines and Streptococcus pneumoniae colonisation in children in South Africa: a single-centre, open-label, randomised trial.<\/a><\/span>  Lancet Child Adolesc Health<\/span> 7(5):326-335<\/span><\/p>

<\/p>

Walsh EE; P\u00e9rez Marc G; Zareba AM; Falsey AR; Jiang Q; Patton M; Polack FP; Llapur C; Doreski PA; Ilangovan K; R\u00e4met M; Fukushima Y; Hussen N; Bont LJ; Cardona J; DeHaan E; Castillo Villa G; Ingilizova M; Eiras D; Mikati T; Shah RN; Schneider K; Cooper D; Koury K; Lino MM; Anderson AS; Jansen KU; Swanson KA; Gurtman A; Gruber WC; Schmoele-Thoma B<\/span>, 2023<\/span>. Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults.<\/a><\/span>  N Engl J Med<\/span> 388(16):1465-1477<\/span><\/p>

<\/p>

Englund JA; Cohen RA; Bianco V; Domachowske JB; Langley JM; Madhi SA; Zaman K; Bueso A; Ceballos A; Cousin L; Gandhi S; Gruselle O; Jose L; Klein NP; Koen A; Puthanakit T; Shi M; Silas P; Tangsathapornpong A; Teeratakulpisarn J; Vesikari T; Haars G; Leach A; Stoszek SK; Dieussaert I<\/span>, 2023<\/span>. Evaluation of Clinical Case Definitions for Respiratory Syncytial Virus Lower Respiratory Tract Infection in Young Children.<\/a><\/span>  J Pediatric Infect Dis Soc<\/span> 12(5):273-281<\/span><\/p>

<\/p>

Cotton MF; Madhi SA; Luabeya AK; Tameris M; Hesseling AC; Shenje J; Schoeman E; Hatherill M; Desai S; Kapse D; Br\u00fcckner S; Koen A; Jose L; Moultrie A; Bhikha S; Walzl G; Gutschmidt A; Kotze LA; Allies DL; Loxton AG; Shaligram U; Abraham M; Johnstone H; Grode L; Kaufmann SHE; Kulkarni PS<\/span>, 2022<\/span>. Safety and immunogenicity of VPM1002 versus BCG in South African newborn babies: a randomised, phase 2 non-inferiority double-blind controlled trial.<\/a><\/span>  Lancet Infect Dis<\/span> 22(10):1472-1483<\/span><\/p>

<\/p>

Madhi SA; Koen AL; Izu A; Fairlie L; Cutland CL; Baillie V; Padayachee SD; Dheda K; Barnabas SL; Bhorat QE; Briner C; Aley PK; Bhikha S; Hermanus T; Horne E; Jose A; Kgagudi P; Lambe T; Masenya M; Masilela M; Mkhize N; Moultrie A; Mukendi CK; Moyo-Gwete T; Nana AJ; Nzimande A; Patel F; Rhead S; Taoushanis C; Thombrayil A; van Eck S; Voysey M; Villafana TL; Vekemans J; Gilbert SC; Pollard AJ; Moore PL; Kwatra G<\/span>, 2021<\/span>. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B\/2A trial.<\/a><\/span>  Lancet HIV<\/span> 8(9):e568-e580<\/span><\/p>

<\/p>

Shinde V; Bhikha S; Hoosain Z; Archary M; Bhorat Q; Fairlie L; Lalloo U; Masilela MSL; Moodley D; Hanley S; Fouche L; Louw C; Tameris M; Singh N; Goga A; Dheda K; Grobbelaar C; Kruger G; Carrim-Ganey N; Baillie V; de Oliveira T; Lombard Koen A; Lombaard JJ; Mngqibisa R; Bhorat AE; Benad\u00e9 G; Lalloo N; Pitsi A; Vollgraaff PL; Luabeya A; Esmail A; Petrick FG; Oommen-Jose A; Foulkes S; Ahmed K; Thombrayil A; Fries L; Cloney-Clark S; Zhu M; Bennett C; Albert G; Faust E; Plested JS; Robertson A; Neal S; Cho I; Glenn GM; Dubovsky F; Madhi SA<\/span>, 2021<\/span>. Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant.<\/a><\/span>  N Engl J Med<\/span> 384(20):1899-1909<\/span><\/p>

<\/p>

Madhi SA; Baillie V; Cutland CL; Voysey M; Koen AL; Fairlie L; Padayachee SD; Dheda K; Barnabas SL; Bhorat QE; Briner C; Kwatra G; Ahmed K; Aley P; Bhikha S; Bhiman JN; Bhorat AE; du Plessis J; Esmail A; Groenewald M; Horne E; Hwa SH; Jose A; Lambe T; Laubscher M; Malahleha M; Masenya M; Masilela M; McKenzie S; Molapo K; Moultrie A; Oelofse S; Patel F; Pillay S; Rhead S; Rodel H; Rossouw L; Taoushanis C; Tegally H; Thombrayil A; van Eck S; Wibmer CK; Durham NM; Kelly EJ; Villafana TL; Gilbert S; Pollard AJ; de Oliveira T; Moore PL; Sigal A; Izu A<\/span>, 2021<\/span>. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant.<\/a><\/span>  N Engl J Med<\/span> 384(20):1885-1898<\/span><\/p>

<\/p>

Voysey M; Costa Clemens SA; Madhi SA; Weckx LY; Folegatti PM; Aley PK; Angus B; Baillie VL; Barnabas SL; Bhorat QE; Bibi S; Briner C; Cicconi P; Clutterbuck EA; Collins AM; Cutland CL; Darton TC; Dheda K; Dold C; Duncan CJA; Emary KRW; Ewer KJ; Flaxman A; Fairlie L; Faust SN; Feng S; Ferreira DM; Finn A; Galiza E; Goodman AL; Green CM; Green CA; Greenland M; Hill C; Hill HC; Hirsch I; Izu A; Jenkin D; Joe CCD; Kerridge S; Koen A; Kwatra G; Lazarus R; Libri V; Lillie PJ; Marchevsky NG; Marshall RP; Mendes AVA; Milan EP; Minassian AM; McGregor A; Mujadidi YF; Nana A; Padayachee SD; Phillips DJ; Pittella A; Plested E; Pollock KM; Ramasamy MN; Ritchie AJ; Robinson H; Schwarzbold AV; Smith A; Song R; Snape MD; Sprinz E; Sutherland RK; Thomson EC; T\u00f6r\u00f6k ME; Toshner M; Turner DPJ; Vekemans J; Villafana TL; White T; Williams CJ; Douglas AD; Hill AVS; Lambe T; Gilbert SC; Pollard AJ<\/span>, 2021<\/span>. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.<\/a><\/span>  Lancet<\/span> 397(10277):881-891<\/span><\/p>

<\/p>

Koen A; Madhi S; Lyabis O; Vidor E; Cowper B; Marais T; Patel D; Vigne C<\/span>, 2021<\/span>. Immunogenicity and safety of a hexavalent pediatric vaccine in HIV-exposed infected and uninfected infants in Republic of South Africa.<\/a><\/span>  Hum Vaccin Immunother<\/span> 17(6):1770-1778<\/span><\/p>

<\/p>

Voysey M; Clemens SAC; Madhi SA; Weckx LY; Folegatti PM; Aley PK; Angus B; Baillie VL; Barnabas SL; Bhorat QE; Bibi S; Briner C; Cicconi P; Collins AM; Colin-Jones R; Cutland CL; Darton TC; Dheda K; Duncan CJA; Emary KRW; Ewer KJ; Fairlie L; Faust SN; Feng S; Ferreira DM; Finn A; Goodman AL; Green CM; Green CA; Heath PT; Hill C; Hill H; Hirsch I; Hodgson SHC; Izu A; Jackson S; Jenkin D; Joe CCD; Kerridge S; Koen A; Kwatra G; Lazarus R; Lawrie AM; Lelliott A; Libri V; Lillie PJ; Mallory R; Mendes AVA; Milan EP; Minassian AM; McGregor A; Morrison H; Mujadidi YF; Nana A; O'Reilly PJ; Padayachee SD; Pittella A; Plested E; Pollock KM; Ramasamy MN; Rhead S; Schwarzbold AV; Singh N; Smith A; Song R; Snape MD; Sprinz E; Sutherland RK; Tarrant R; Thomson EC; T\u00f6r\u00f6k ME; Toshner M; Turner DPJ; Vekemans J; Villafana TL; Watson MEE; Williams CJ; Douglas AD; Hill AVS; Lambe T; Gilbert SC; Pollard AJ<\/span>, 2021<\/span>. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.<\/a><\/span>  Lancet<\/span> 397(10269):99-111<\/span><\/p>

<\/p>

Kurokawa N; Robinson MK; Bernard C; Kawaguchi Y; Koujin Y; Koen A; Madhi S; Polasek TM; McNeal M; Dargis M; Couture MM; Tr\u00e9panier S; Forrest BD; Tsutsui N<\/span>, 2021<\/span>. Safety and immunogenicity of a plant-derived rotavirus-like particle vaccine in adults, toddlers and infants.<\/a><\/span>  Vaccine<\/span> 39(39):5513-5523<\/span><\/p>

<\/p>

Mutsaerts EAML; Nunes MC; Bhikha S; Ikulinda BT; Jose L; Koen A; Moultrie A; Grobbee DE; Klipstein-Grobusch K; Weinberg A; Madhi SA<\/span>, 2020<\/span>. Short-term immunogenicity and safety of hepatitis-A and varicella vaccines in HIV-exposed uninfected and HIV-unexposed South African children.<\/a><\/span>  Vaccine<\/span> 38(22):3862-3868<\/span><\/p>

<\/p>

Madhi SA; Moreira M; Koen A; van Niekerk N; de Gouveia L; Jose L; Cutland CL; Fran\u00e7ois N; Schoonbroodt S; Ruiz-Gui\u00f1az\u00fa J; Yarzabal JP; Borys D; Schuerman L<\/span>, 2020<\/span>. Impact of HIV status and vaccination schedule on bacterial nasopharyngeal carriage following infant immunisation with the pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in South Africa.<\/a><\/span>  Vaccine<\/span> 38(10):2350-2360<\/span><\/p>

<\/p>

Groome MJ; Fairlie L; Morrison J; Fix A; Koen A; Masenya M; Jose L; Madhi SA; Page N; McNeal M; Dally L; Cho I; Power M; Flores J; Cryz S<\/span>, 2020<\/span>. Safety and immunogenicity of a parenteral trivalent P2-VP8 subunit rotavirus vaccine: a multisite, randomised, double-blind, placebo-controlled trial.<\/a><\/span>  Lancet Infect Dis<\/span> 20(7):851-863<\/span><\/p>

<\/p>

Madhi SA; Polack FP; Piedra PA; Munoz FM; Trenholme AA; Sim\u00f5es EAF; Swamy GK; Agrawal S; Ahmed K; August A; Baqui AH; Calvert A; Chen J; Cho I; Cotton MF; Cutland CL; Englund JA; Fix A; Gonik B; Hammitt L; Heath PT; de Jesus JN; Jones CE; Khalil A; Kimberlin DW; Libster R; Llapur CJ; Lucero M; P\u00e9rez Marc G; Marshall HS; Masenya MS; Martin\u00f3n-Torres F; Meece JK; Nolan TM; Osman A; Perrett KP; Plested JS; Richmond PC; Snape MD; Shakib JH; Shinde V; Stoney T; Thomas DN; Tita AT; Varner MW; Vatish M; Vrbicky K; Wen J; Zaman K; Zar HJ; Glenn GM; Fries LF<\/span>, 2020<\/span>. Respiratory Syncytial Virus Vaccination during Pregnancy and Effects in Infants.<\/a><\/span>  N Engl J Med<\/span> 383(5):426-439<\/span><\/p>

<\/p>

Savulescu DM; Groome M; Malfeld SCK; Madhi S; Koen A; Jones S; Duxbury V; Scheuermaier K; De Assis Rosa D; Suchard M<\/span>, 2020<\/span>. HLA antibody repertoire in infants suggests selectivity in transplacental crossing.<\/a><\/span>  Am J Reprod Immunol<\/span> 84(2):e13264<\/span><\/p>

<\/p>

Nunes MC; Moreira M; Koen A; van Niekerk N; Jose L; Cutland CL; Fran\u00e7ois N; Schoonbroodt S; Ruiz-Gui\u00f1az\u00fa J; Yarzabal JP; Borys D; Schuerman L; Madhi SA<\/span>, 2020<\/span>. Bacterial nasopharyngeal carriage following infant immunization with pneumococcal conjugate vaccines according to a 2+1 schedule in children in South Africa: an exploratory analysis of two clinical trials.<\/a><\/span>  Expert Rev Vaccines<\/span> 19(12):1177-1189<\/span><\/p>

<\/p>

Madhi SA; Mutsaerts EA; Izu A; Boyce W; Bhikha S; Ikulinda BT; Jose L; Koen A; Nana AJ; Moultrie A; Roalfe L; Hunt A; Goldblatt D; Cutland CL; Dorfman JR<\/span>, 2020<\/span>. Immunogenicity of a single-dose compared with a two-dose primary series followed by a booster dose of ten-valent or 13-valent pneumococcal conjugate vaccine in South African children: an open-label, randomised, non-inferiority trial.<\/a><\/span>  Lancet Infect Dis<\/span> 20(12):1426-1436<\/span><\/p>

<\/p>

Mutsaerts EAML; Nunes MC; Bhikha S; Ikulinda BT; Boyce W; Jose L; Koen A; Moultrie A; Cutland CL; Grobbee DE; Klipstein-Grobusch K; Madhi SA<\/span>, 2019<\/span>. Immunogenicity and Safety of an Early Measles Vaccination Schedule at 6 and 12 Months of Age in Human Immunodeficiency Virus (HIV)-Unexposed and HIV-Exposed, Uninfected South African Children.<\/a><\/span>  J Infect Dis<\/span> 220(9):1529-1538<\/span><\/p>

<\/p>

Koen A; Jose L; Madhi SA; Fix A; Cryz S; Groome MJ<\/span>, 2019<\/span>. Neutrophil Counts in Healthy South African Infants: Implications for Enrollment and Adverse Event Grading in Clinical Trials in an African Setting.<\/a><\/span>  J Pediatr X<\/span> 1:100005<\/span><\/p>

<\/p>

Madhi SA; Koen A; Jose L; Moreira M; van Niekerk N; Cutland C; Fran\u00e7ois N; Ruiz-Gui\u00f1az\u00fa J; Yarzabal JP; Borys D; Schuerman L<\/span>, 2017<\/span>. Immunization with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) according to different schedules in infants in South Africa: a phase III trial.<\/a><\/span>  Expert Rev Vaccines<\/span> 16(6):641-656<\/span><\/p>

<\/p>

Madhi SA; Koen A; Jose L; van Niekerk N; Adrian PV; Cutland C; Fran\u00e7ois N; Ruiz-Gui\u00f1az\u00fa J; Yarzabal JP; Moreira M; Borys D; Schuerman L<\/span>, 2017<\/span>. Vaccination with 10-valent pneumococcal conjugate vaccine in infants according to HIV status.<\/a><\/span>  Medicine (Baltimore)<\/span> 96(2):e5881<\/span><\/p>

<\/p>

Groome MJ; Koen A; Fix A; Page N; Jose L; Madhi SA; McNeal M; Dally L; Cho I; Power M; Flores J; Cryz S<\/span>, 2017<\/span>. Safety and immunogenicity of a parenteral P2-VP8-P[8] subunit rotavirus vaccine in toddlers and infants in South Africa: a randomised, double-blind, placebo-controlled trial.<\/a><\/span>  Lancet Infect Dis<\/span> 17(8):843-853<\/span><\/p>

<\/p>

Madhi SA; Koen A; Cutland CL; Jose L; Govender N; Wittke F; Olugbosi M; Sobanjo-Ter Meulen A; Baker S; Dull PM; Narasimhan V; Slobod K<\/span>, 2017<\/span>. Antibody Kinetics and Response to Routine Vaccinations in Infants Born to Women Who Received an Investigational Trivalent Group B Streptococcus Polysaccharide CRM197-Conjugate Vaccine During Pregnancy.<\/a><\/span>  Clin Infect Dis<\/span> 65(11):1897-1904<\/span><\/p>

<\/p>

Madhi SA; Cutland CL; Jose L; Koen A; Govender N; Wittke F; Olugbosi M; Meulen AS; Baker S; Dull PM; Narasimhan V; Slobod K<\/span>, 2016<\/span>. Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in healthy women and their infants: a randomised phase 1b\/2 trial.<\/a><\/span>  Lancet Infect Dis<\/span> 16(8):923-34<\/span><\/p>

<\/p>

Heyderman RS; Madhi SA; French N; Cutland C; Ngwira B; Kayambo D; Mboizi R; Koen A; Jose L; Olugbosi M; Wittke F; Slobod K; Dull PM<\/span>, 2016<\/span>. Group B streptococcus vaccination in pregnant women with or without HIV in Africa: a non-randomised phase 2, open-label, multicentre trial.<\/a><\/span>  Lancet Infect Dis<\/span> 16(5):546-555<\/span><\/p>

<\/p>

Dangor Z; Lala SG; Cutland CL; Koen A; Jose L; Nakwa F; Ramdin T; Fredericks J; Wadula J; Madhi SA<\/span>, 2015<\/span>. Burden of invasive group B Streptococcus disease and early neurological sequelae in South African infants.<\/a><\/span>  PLoS One<\/span> 10(4):e0123014<\/span><\/p>

<\/p>

Groome MJ; Moon SS; Velasquez D; Jones S; Koen A; van Niekerk N; Jiang B; Parashar UD; Madhi SA<\/span>, 2014<\/span>. Effect of breastfeeding on immunogenicity of oral live-attenuated human rotavirus vaccine: a randomized trial in HIV-uninfected infants in Soweto, South Africa.<\/a><\/span>  Bull World Health Organ<\/span> 92(4):238-45<\/span><\/p>

<\/p>

Jones SA; Groome M; Koen A; Van Niekerk N; Sewraj P; Kuwanda L; Izu A; Adrian PV; Madhi SA<\/span>, 2013<\/span>. Immunogenicity of seven-valent pneumococcal conjugate vaccine administered at 6, 14 and 40 weeks of age in South African infants.<\/a><\/span>  PLoS One<\/span> 8(8):e72794<\/span><\/p>

<\/p>

Madhi SA; Koen A; Cutland C; Groome M; Santos-Lima E<\/span>, 2013<\/span>. Antibody persistence and booster vaccination of a fully liquid hexavalent vaccine coadministered with measles\/mumps\/rubella and varicella vaccines at 15-18 months of age in healthy South African infants.<\/a><\/span>  Pediatr Infect Dis J<\/span> 32(8):889-97<\/span><\/p>

<\/p>

Nunes MC; Shiri T; van Niekerk N; Cutland CL; Groome MJ; Koen A; von Gottberg A; de Gouveia L; Klugman KP; Adrian PV; Madhi SA<\/span>, 2013<\/span>. Acquisition of Streptococcus pneumoniae in pneumococcal conjugate vaccine-na\u00efve South African children and their mothers.<\/a><\/span>  Pediatr Infect Dis J<\/span> 32(5):e192-205<\/span><\/p>

<\/p>

Madhi SA; Maskew M; Koen A; Kuwanda L; Besselaar TG; Naidoo D; Cohen C; Valette M; Cutland CL; Sanne I<\/span>, 2011<\/span>. Trivalent inactivated influenza vaccine in African adults infected with human immunodeficient virus: double blind, randomized clinical trial of efficacy, immunogenicity, and safety.<\/a><\/span>  Clin Infect Dis<\/span> 52(1):128-37<\/span><\/p>

<\/p>

Publication list retrieved from NCBI<\/a> using ImpactPubs<\/a><\/p>.<\/div><\/div><\/div><\/div><\/p>\n","protected":false},"excerpt":{"rendered":"

Joined the Vaccines and Infectious Diseases Analytics (VIDA) Research Unit as a medical officer in 2008.<\/p>\n","protected":false},"author":1,"featured_media":806,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","format":"standard","meta":{"footnotes":""},"faq_category":[44],"class_list":["post-910","avada_faq","type-avada_faq","status-publish","format-standard","has-post-thumbnail","hentry","faq_category-researchers"],"acf":[],"_links":{"self":[{"href":"https:\/\/wits-vida.org\/wp-json\/wp\/v2\/avada_faq\/910","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/wits-vida.org\/wp-json\/wp\/v2\/avada_faq"}],"about":[{"href":"https:\/\/wits-vida.org\/wp-json\/wp\/v2\/types\/avada_faq"}],"author":[{"embeddable":true,"href":"https:\/\/wits-vida.org\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/wits-vida.org\/wp-json\/wp\/v2\/comments?post=910"}],"version-history":[{"count":10,"href":"https:\/\/wits-vida.org\/wp-json\/wp\/v2\/avada_faq\/910\/revisions"}],"predecessor-version":[{"id":4272,"href":"https:\/\/wits-vida.org\/wp-json\/wp\/v2\/avada_faq\/910\/revisions\/4272"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/wits-vida.org\/wp-json\/wp\/v2\/media\/806"}],"wp:attachment":[{"href":"https:\/\/wits-vida.org\/wp-json\/wp\/v2\/media?parent=910"}],"wp:term":[{"taxonomy":"faq_category","embeddable":true,"href":"https:\/\/wits-vida.org\/wp-json\/wp\/v2\/faq_category?post=910"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}